Anti-idiotype antibodies that specifically bind to anti-human TIM-3 antibodies and uses thereof

By specifically binding to anti-idiotype monoclonal antibodies against human TIM-3 monoclonal antibodies, the non-specific interference problem of anti-TIM-3 antibody detection in complex matrix is ​​solved, and high-sensitivity blood drug concentration and anti-drug antibody detection is achieved. Significantly improves the accuracy of the analysis.

CN119039448APending Publication Date: 2024-11-29NANJING LEADS BIOLABS CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310578446.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-22
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

When detecting and analyzing anti-TIM-3 antibodies, the prior art faces the problem of non-specific binding interference in complex substrates, and it is difficult to accurately measure blood drug concentration and detect anti-drug antibodies.

Method used

Develop anti-idiotype monoclonal antibodies that specifically bind anti-human TIM-3 monoclonal antibodies to prepare detection kits for the preparation of high sensitivity to block anti-TIM The binding of -3 antibody to TIM-3 protein is used in biological analysis methods.

Benefits of technology

Two anti-idiotype antibodies specifically binding to anti-human TIM-3 monoclonal antibodies are provided, which can efficiently detect anti-TIM-3 antibodies in complex matrix, significantly improving the accuracy and sensitivity of the detection, and are suitable for blood drug concentrations. Detection and detection of antibiotic antibodies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119039448A_ABST
    Figure CN119039448A_ABST
Patent Text Reader

Abstract

The present invention discloses anti-idiotypic antibodies that specifically bind to anti-human TIM-3 antibodies and uses thereof. The invention relates to an anti-idiotypic monoclonal antibody which is specifically combined with an anti-human TIM-3 antibody, wherein the anti-idiotypic monoclonal antibody is selected from any one of anti-idiotypic antibodies 3469-09 and 3469-11. The invention provides two anti-idiotype monoclonal antibodies which are specifically combined with an anti-human TIM-3 monoclonal antibody. The two anti-idiotype monoclonal antibodies can be specifically combined with an anti-human TIM-3 antibody, and can block the combination of the anti-human TIM-3 antibody and a human TIM-3 protein, so that the two anti-idiotype monoclonal antibodies are both neutralizing type anti-idiotype antibodies.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to an anti-idiotypic monoclonal antibody specifically binding to an anti-human TIM-3 antibody, and a preparation method and use thereof. Background Art

[0002] Immune checkpoint TIM-3 and related antibody drugs

[0003] With the successful clinical application of immune checkpoint inhibitors, especially anti-PD-1 / PD-L1 antibody drugs in the anti-tumor field, research on immune checkpoint-related mechanisms has become increasingly popular, and new immune checkpoint proteins have gradually seen more clinical application reports (Maria de Miguels. et al. Cancer Cell. 2020 Sep 14; 38(3): 326-333.).

[0004] TIM-3 is a negatively regulated immune checkpoint protein expressed on the surface of various immune cells, including T cells, dendritic cells (DCs), B cells, macrophages and natural killer cells. The main ligands of TIM-3 are galectin-9 (Gal-9), carcinoembryonic antigen cell adhesion molecule-1 (CEACAM-1), high mobility group protein B1 (HMGB1) and phosphatidylserine (PS) (Yoshikane Kikushige et al. Int J Hematol. 2013 Dec; 98 (6): 627-33.). In CD8+ T lymphocytes, TIM-3 and other inhibitory immune checkpoints, such as PD-1, CD160, etc., are considered to be related to T cell differentiation and activation, and to the release of IFN-γ and TNF-α. At the same time, blocking the TIM-3 pathway may inhibit the activation of Treg (Madhumita Das et al. Immunol Rev. 2017 Mar; 276(1): 97-111.).

[0005] Novartis's Sabotolimab is a monoclonal antibody drug targeting human TIM-3. This antibody drug can not only target myeloid leukemia cells, but also inhibit the exhaustion of immune cells (Gorden J. Freeman et al. Immunological Reviews 2010 Vol. 235: 172–189.). In a clinical study combined with decitabine or azacitidine (NCT03066648), the total effective rate (ORR) in 34 patients with acute lymphoblastic leukemia was 40%, and the total effective rate in 35 patients with myelodysplastic syndrome reached 56.9% (Andrew M. Brunner et al. Blood (2021) 138 (Supplement 1): 244.). The encouraging results confirm the drugability of this target.

[0006] Anti-idiotypic antibodies

[0007] Antibodies are immunoglobulins produced by B cells that can specifically bind to certain unique protein sequences. In a specific antibody molecule, the specific antigenic determinant (AntigenicDeterminants) part of its variable region (Variable Region) is called the antibody's idiotope. Some idiotopes completely overlap with the antibody's antigen-binding paratope; some idiotopes are located outside the paratope of the variable region; and other idiotopes, in addition to the paratope, also include other sequences on the variable region. All idiotopes and paratopes in an antibody molecule are collectively referred to as the antibody's idiotype (Shing Yi Pan et al. Future Sci OA. 2020 Oct 29; 7 (2): FSO648.).

[0008] Anti-idiotype antibodies (Anti-ID Abs) are specific antibodies produced against the antigenic determinant (idiotype) of the variable region of an antibody. Generally, the antigenic determinant sequence or the full-length or partial sequence of the antibody is used as an immunogen, and animals such as rabbits and mice are immunized, and then monoclonal expression cell lines are obtained through hybridoma cell construction or single B cell screening, and then anti-idiotype antibody monoclonal antibodies are obtained through amplification culture and immunoaffinity purification (Shing Yi Pan et al. Future Sci OA. 2020 Oct 29; 7 (2): FSO648.).

[0009] Anti-idiotypic antibodies can be divided into neutralizing anti-idiotypic antibodies and non-neutralizing anti-idiotypic antibodies according to whether the binding epitope of the anti-idiotypic antibody and the antibody is the same as the binding epitope of the antibody and antigen. Both types of antibodies are widely used in the determination of antibody drug content (including free form, bound form and total amount) in preclinical and clinical development, as well as the development and determination of anti-drug antibody detection methods and receptor occupancy methods.

[0010] When the anti-TIM-3 antibody is injected into the body as a drug, it is necessary to develop a detection method for the anti-LAG-3 antibody when conducting pharmacokinetics or other studies on the antibody itself. Whether it is the detection of blood, tissue fluid, cerebrospinal fluid or tissue homogenate, the complex matrix contains various endogenous proteins, which may bind to the key reagents of the method non-specifically or specifically. This interference can be avoided or greatly reduced by selecting anti-idiotypic antibodies as the key reagents of the method (Pendly et al. Bioanalysis (2011) 3 (7), 703-706). Based on this, the anti-idiotypic antibodies of the anti-TIM-3 antibodies obtained by the present invention are used to develop related bioanalysis methods, such as blood drug concentration detection or anti-drug antibody detection. Summary of the invention

[0011] Other features and advantages of the present disclosure will be apparent from the following detailed description and examples, which should not be construed as limiting.The contents of all references, Genbank entries, patents, and published patent applications cited throughout this application are expressly incorporated herein by reference.

[0012] The object of the present invention is to provide an anti-idiotypic monoclonal antibody that specifically binds to an anti-human TIM-3 monoclonal antibody in view of the above-mentioned deficiencies in the prior art.

[0013] Another object of the present invention is to provide the use of an anti-idiotypic monoclonal antibody that specifically binds to an anti-human TIM-3 monoclonal antibody.

[0014] Another object of the present invention is to provide a composition containing an anti-idiotypic monoclonal antibody that specifically binds to an anti-human TIM-3 monoclonal antibody.

[0015] The purpose of the present invention can be achieved through the following technical solutions:

[0016] An anti-idiotypic antibody or an antigenic determinant thereof that specifically binds to an anti-human TIM-3 antibody, wherein the anti-idiotypic antibody or an antigenic determinant thereof comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises: a CDR1 region shown in SEQ ID NO.1 or SEQ ID NO.9, a CDR2 region shown in SEQ ID NO.2 or SEQ ID NO.10, and a CDR3 region shown in SEQ ID NO.3 or SEQ ID NO.11; the light chain variable region comprises: a CDR1 region shown in SEQ ID NO.4 or SEQ ID NO.12, a CDR2 region shown in SEQ ID NO.5 or SEQ ID NO.13, and a CDR3 region shown in SEQ ID NO.6 or SEQ ID NO.14.

[0017] As a preferred embodiment of the present invention, the anti-idiotypic antibody or its antigenic determinant that specifically binds to the anti-human TIM-3 antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises: a CDR1 region shown in SEQ ID NO.1, a CDR2 region shown in SEQ ID NO.2, and a CDR3 region shown in SEQ ID NO.3; the light chain variable region comprises: a CDR1 region shown in SEQ ID NO.4, a CDR2 region shown in SEQ ID NO.5, and a CDR3 region shown in SEQ ID NO.6; or, the anti-idiotypic antibody or its antigenic determinant that specifically binds to the anti-human TIM-3 antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises: a CDR1 region shown in SEQ ID NO.9, a CDR2 region shown in SEQ ID NO.10, and a CDR3 region shown in SEQ ID NO.11; the light chain variable region comprises: a CDR1 region shown in SEQ ID NO.12, a CDR2 region shown in SEQ ID NO.13, and a CDR3 region shown in SEQ ID NO.14.

[0018] As a preferred embodiment of the present invention, the amino acid sequence of the heavy chain variable region of the anti-idiotypic antibody or its antigenic determinant that specifically binds to the anti-human TIM-3 antibody is as shown in SEQ ID NO.7 or SEQ ID NO.15.

[0019] As a preferred embodiment of the present invention, the amino acid sequence of the light chain variable region of the anti-idiotypic antibody or its antigenic determinant that specifically binds to the anti-human TIM-3 antibody is as shown in SEQ ID NO.8 or SEQ ID NO.16.

[0020] As a preferred embodiment of the present invention, the constant region of the anti-idiotypic antibody that specifically binds to the anti-human TIM-3 antibody is selected from the common constant region of mouse / human IgG.

[0021] As a preferred embodiment of the present invention, the amino acid sequence of the heavy chain variable region of the anti-idiotypic antibody or its antigenic determinant that specifically binds to the anti-human TIM-3 antibody is shown in SEQ ID NO.7, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO.8. As a further preferred embodiment of the present invention, the heavy chain of the anti-idiotypic antibody that specifically binds to the anti-human TIM-3 antibody is IgG1, and the light chain is κ type.

[0022] As a preferred embodiment of the present invention, the amino acid sequence of the heavy chain variable region of the anti-idiotypic antibody or its antigenic determinant that specifically binds to the anti-human TIM-3 antibody is shown in SEQ ID NO. 15, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO. 16. As a further preferred embodiment of the present invention, the heavy chain of the anti-idiotypic antibody that specifically binds to the anti-human TIM-3 antibody is IgG2B, and the light chain is κ type.

[0023] As a preferred embodiment of the present invention, the anti-idiotypic antibody that specifically binds to the anti-human TIM-3 antibody is a monoclonal antibody; and the antigenic determinant is selected from Fab, F(ab′)2 or scFv.

[0024] Use of the anti-idiotypic antibody or its antigenic determinant site described in the present invention in preparing a reagent for detecting anti-TIM-3 antibodies.

[0025] The anti-idiotypic antibody or its antigenic determinant site described in the present invention is used to inhibit the binding of TIM-3 protein to its antibody.

[0026] As a preferred embodiment of the present invention, the antibody against TIM-3 protein is a monoclonal antibody against TIM-3 protein.

[0027] A kit comprises the anti-idiotypic antibody or its antigenic determinant site that specifically binds to the anti-human TIM-3 antibody.

[0028] As a preferred embodiment of the present invention, the kit contains the anti-idiotypic antibody or its antigenic determinant site that specifically binds to the anti-human TIM-3 antibody.

[0029] A double antibody sandwich detection kit for anti-TIM-3 antibodies, comprising two anti-idiotypic antibodies that specifically bind to anti-human TIM-3 antibodies of the present invention, wherein one anti-idiotypic antibody that specifically binds to anti-human TIM-3 antibodies of the present invention is labeled with biotin. For example, in an embodiment of the present invention, the double antibody sandwich detection kit for anti-TIM-3 antibodies comprises anti-idiotypic antibody 3469-09 labeled with biotin, and another anti-idiotypic antibody 3469-11. The heavy chain variable region of anti-idiotypic antibody 3469-09 comprises the amino acid sequence shown in SEQ ID NO.7, and the light chain variable region comprises the amino acid sequence shown in SEQ ID NO.8; the heavy chain variable region of anti-idiotypic antibody 3469-11 comprises the amino acid sequence shown in SEQ ID NO.15, and the light chain variable region comprises the amino acid sequence shown in SEQ ID NO.16.

[0030] Beneficial effects:

[0031] The present invention provides two anti-idiotypic antibodies that specifically bind to anti-human TIM-3 monoclonal antibodies. Both anti-idiotypic monoclonal antibodies can specifically bind to anti-human TIM-3 antibodies and can block the binding of anti-human TIM-3 antibodies to human TIM-3 protein, indicating that both anti-idiotypic antibodies are neutralizing anti-idiotypic antibodies. The anti-idiotypic antibodies that specifically bind to anti-human TIM-3 monoclonal antibodies of the present invention can be used to prepare a detection kit with high sensitivity. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] Figure 1 The binding activity of the candidate anti-idiotypic antibodies to the anti-human TIM-3 antibody was shown.

[0033] Figure 2 The candidate anti-idiosyncratic antibodies were shown to inhibit the activity of anti-human TIM-3 antibodies in binding to human TIM-3 protein.

[0034] Figure 3 The double antibody sandwich assay was shown to be useful for the quantitative detection of anti-TIM-3 antibodies in human serum matrix. DETAILED DESCRIPTION

[0035] Example 1: Preparation of anti-idiotypic antibodies

[0036] 1.1 Preparation of immunogen

[0037] Pepsin (Sangong Biotechnology, Catalog No.: A600688) was incubated with 2 mg / mL of anti-human TIM-3 antibody (publication number: TIM3-6.12 in CN111989341A) at room temperature for 30 minutes, and the flow-through liquid was collected in a flow-through mode through a protein A affinity purification column (General Electric Company, Catalog No.: 17040301), wherein the antibody fragment of the F(ab')2 structure was the target protein, and an ultrafiltration concentration tube (Merck Millipore, Catalog No.: AmiconUltra-0.5mL, 10KD) was used to remove small volume impurities and concentrate the liquid. Polyacrylamide gel electrophoresis confirmed that the purity of the F(ab')2 antibody fragment reached more than 90%, which can be used as the immunogen hybridoma immunization for subsequent animal immunization.

[0038] 1.2 Hybridoma Immunization

[0039] Hybridoma immunization was performed by Suzhou Unoco Biotechnology Co., Ltd., and BALB / c mice were immunized with the F(ab')2 antibody fragment prepared above at a dosage of 100 μg / mouse / time, once every two weeks, for a total of four times. After the third and fourth immunizations, mice with the highest titer of anti-idiotypic antibodies in the serum were selected, and spleen cells of the animals were obtained and fused with myeloma cells to form hybridoma cells; then, monoclonal cells expressing antibodies with the strongest binding ability to anti-TIM-3 antibodies were screened out through monoclonal screening.

[0040] 1.3 Immunoaffinity purification

[0041] The monoclonal hybridoma cells obtained in step 1.2 were cultured, and then the obtained culture supernatant was subjected to immunoaffinity purification to obtain anti-idiotypic antibodies. Immunoaffinity purification is divided into two steps: the first step is to obtain anti-idiotypic antibodies with higher purity by coupling anti-TIM-3 antibodies to affinity purification columns (General Electric Company, Catalog No.: 17043001) in a binding elution mode (collecting eluate); the second step is to couple human IgG (Jackson ImmunoResearch, Catalog No.: 009-000-003) to affinity purification columns, and the eluate obtained in the first step is eluted again to obtain anti-idiotypic antibodies with higher purity in a flow-through mode.

[0042] Example 2: Binding of anti-idiotypic antibodies to anti-human TIM-3 antibodies

[0043] ELISA assay to determine the binding of anti-idiotypic antibodies to anti-human TIM-3 antibodies

[0044] Anti-human TIM-3 antibody (Patent Application Publication No.: CN111989341A, TIM3-6.12) was fixed to a 96-well plate by incubation overnight at 4°C. The plate was then blocked by incubation at 37°C with 1% BSA in PBS for 1 hour. After blocking, the plate was washed 3 times with PBST (PBS containing 0.05% Tween20). A series of serial dilutions of anti-idiotype antibodies (3469-09 and 3469-11) were prepared in binding buffer (PBS containing 0.05% Tween20 and 0.5% BSA), added to the plate and incubated together at 37°C for 1 hour. After binding, the plates were washed three times with PBST, incubated for 1 hour at 37°C with peroxidase-labeled donkey anti-human IgG (Jackson Immuno Research, Cat. No. 109-035-098) diluted 1 / 20,000 in binding buffer, washed again, developed with TMB and stopped with 1M H2SO4.

[0045] The anti-idiotypic antibody binds to the EC of the anti-human TIM-3 antibody 50 and representative binding curves are shown in Figure 1 middle.

[0046] The results showed that both anti-idiosyncratic antibodies 3469-09 and 3469-11 could specifically bind to anti-human TIM-3 antibodies.

[0047] Example 3: Anti-idiotypic antibodies inhibit the binding of anti-human TIM-3 antibodies to human TIM-3 protein

[0048] ELISA assay to determine whether anti-idiotypic antibodies inhibit the binding of anti-human TIM-3 antibodies to human TIM-3 protein

[0049] Anti-human TIM-3 antibodies (Patent Application Publication No.: CN111989341A, TIM3-6.12) were fixed to 96-well plates by incubation at 4°C overnight. The plate was then blocked by incubation with 1% BSA in PBS for 1 hour at 37°C. After blocking, the plate was washed 3 times with PBST (PBS containing 0.05% Tween20). A fixed concentration of human TIM-3-his (Sino-Biological, Cat. No.: 10390-H08H) was prepared in binding buffer (PBS containing 0.05% Tween20 and 0.5% BSA), while serially diluted anti-idiotypic antibodies (3469-09 and 3469-11) were mixed with 50 μL of 20 ng / mL human TIM-3 protein solution, and then added to the plate and incubated at 37°C for 1 hour. After binding, the plates were washed three times with PBST, incubated with peroxidase-labeled anti-his-tag IgG (Convix, Cat. No.: CW0285M) diluted 1 / 5,000 in binding buffer at 37°C for 1 hour, washed again, developed with TMB and stopped with 1 M H2SO4.

[0050] The anti-idiotypic antibody inhibits the IC of the anti-human TIM-3 antibody binding to human TIM-3 50 and representative binding curves are shown in Figure 2 middle.

[0051] The results showed that both anti-idiotypic antibodies 3469-09 and 3469-11 could block the binding of anti-human TIM-3 antibody to human TIM-3 protein, indicating that both anti-idiotypic antibodies were neutralizing anti-idiotypic antibodies.

[0052] Example 4: Anti-idiotypic antibody sequencing

[0053] The anti-idiotypic antibodies 3469-09 and 3469-11 that met the screening requirements were sequenced using high-throughput sequencing (NGS) technology, and the sequencing process was completed by Nanjing GenScript Biotech Co., Ltd.

[0054] The anti-idiotypic antibody 3469-09 has an IgG1 heavy chain and a κ light chain. The heavy chain variable region comprises: a CDR1 region as shown in SEQ ID NO.1; a CDR2 region as shown in SEQ ID NO.2; and a CDR3 region as shown in SEQ ID NO.3; the light chain variable region comprises: a CDR1 region as shown in SEQ ID NO.4; a CDR2 region as shown in SEQ ID NO.5; and a CDR3 region as shown in SEQ ID NO.6; the heavy chain variable region of the anti-idiotypic antibody 3469-09 comprises the amino acid sequence as shown in SEQ ID NO.7, and the light chain variable region comprises the amino acid sequence as shown in SEQ ID NO.8.

[0055] The anti-idiotypic antibody 3469-11 has an IgG1 heavy chain and a κ light chain. It comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises: a CDR1 region as shown in SEQ ID NO.9; a CDR2 region as shown in SEQ ID NO.10; and a CDR3 region as shown in SEQ ID NO.11; the light chain variable region comprises: a CDR1 region as shown in SEQ ID NO.12; a CDR2 region as shown in SEQ ID NO.13; and a CDR3 region as shown in SEQ ID NO.14; the heavy chain variable region of the anti-idiotypic antibody 3469-11 comprises the amino acid sequence as shown in SEQ ID NO.15, and the light chain variable region comprises the amino acid sequence as shown in SEQ ID NO.16.

[0056] Example 5: Detection method of anti-TIM-3 antibodies based on human serum matrix

[0057] To establish a double antibody sandwich method based on human serum matrix, the anti-idiotypic antibody 3469-09 was first biotin-labeled with Sulfo-NHS-LC-Biotin (ThermoFisher, Cat. No. 21335).

[0058] Anti-idiotypic antibody 3469-11 was fixed to a 96-well plate by incubating overnight at 4°C. The plate was then blocked by incubating with 1% BSA in PBS for 1 hour at 37°C. After blocking, the plate was washed 3 times with PBST (PBS containing 0.05% Tween20). Anti-TIM-3 antibodies were prepared in mixed human serum at concentrations of 400 ng / mL and 256 ng / mL, then diluted twice from 256 ng / mL to 2 ng / mL, and the anti-TIM-3 antibody solution of the series concentration was diluted 5 times by binding buffer (PBS containing 0.05% Tween20 and 0.5% BSA), and then added to the plate and incubated together at 37°C for 1 hour. After binding, the plate was washed three times with PBST, mixed with 0.25 μg / mL of biotin-labeled 3468-09 at 37°C, and incubated for 1 hour; after binding, the plate was washed three times with PBST, incubated with 1 / 100 diluted peroxidase-labeled streptavidin (ThermoFisher, Catalog No.: 21130) in binding buffer at 37°C for 1 hour, washed again, developed with TMB and stopped using 1M H2SO4.

[0059] The binding curve of the double antibody sandwich method is shown in Figure 3 .

[0060] The results showed that within the range of 256 ng / mL to 4 ng / mL, the double antibody sandwich method could obtain a curve with an obvious dose-effect relationship. By optimizing appropriate conditions and back-calculating through software fitting, a method for quantitatively detecting anti-TIM-3 antibodies in human serum matrix could be obtained.

Claims

1. an anti-idiotypic antibody that specifically binds to an anti-human TIM-3 antibody or an antigenic determinant thereof, It is characterized in that The anti-idiotypic antibody or its antigenic determinant comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises: a CDR1 region shown in SEQ ID NO.1 or SEQ ID NO.9, a CDR2 region shown in SEQ ID NO.2 or SEQ ID NO.10, and a CDR3 region shown in SEQ ID NO.3 or SEQ ID NO.11; the light chain variable region comprises: a CDR1 region shown in SEQ ID NO.4 or SEQ ID NO.12, a CDR2 region shown in SEQ ID NO.5 or SEQ ID NO.13, and a CDR3 region shown in SEQ ID NO.6 or SEQ ID NO.

14.

2. The anti-idiotypic antibody or its antigenic determinant that specifically binds to the anti-human TIM-3 antibody according to claim 1, It is characterized in that The anti-idiotypic antibody or its antigenic determinant that specifically binds to the anti-human TIM-3 antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises: a CDR1 region shown in SEQ ID NO.1, a CDR2 region shown in SEQ ID NO.2, and a CDR3 region shown in SEQ ID NO.3; the light chain variable region comprises: a CDR1 region shown in SEQ ID NO.4, a CDR2 region shown in SEQ ID NO.5, and a CDR3 region shown in SEQ ID NO.6; Alternatively, the anti-idiotypic antibody or its antigenic determinant that specifically binds to the anti-human TIM-3 antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises: a CDR1 region shown in SEQ ID NO.9, a CDR2 region shown in SEQ ID NO.10, and a CDR3 region shown in SEQ ID NO.11; the light chain variable region comprises: a CDR1 region shown in SEQ ID NO.12, a CDR2 region shown in SEQ ID NO.13, and a CDR3 region shown in SEQ ID NO.

14.

3. The anti-idiotypic antibody or its antigenic determinant that specifically binds to the anti-human TIM-3 antibody according to claim 1, It is characterized in that The amino acid sequence of the heavy chain variable region of the anti-idiotypic antibody or its antigenic determinant that specifically binds to the anti-human TIM-3 antibody is shown in SEQ ID NO.7 or SEQ ID NO.

15.

4. The anti-idiotypic antibody or its antigenic determinant that specifically binds to the anti-human TIM-3 antibody according to claim 1, It is characterized in that The amino acid sequence of the light chain variable region of the anti-idiotypic antibody or its antigenic determinant that specifically binds to the anti-human TIM-3 antibody is the amino acid sequence shown in SEQ ID NO.8 or SEQ ID NO.

16.

5. The anti-idiotypic antibody or its antigenic determinant that specifically binds to the anti-human TIM-3 antibody according to claim 1, It is characterized in that The amino acid sequence of the heavy chain variable region of the anti-idiotypic antibody or its antigenic determinant that specifically binds to the anti-human TIM-3 antibody is shown in SEQ ID NO.7, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO.

8.

6. The anti-idiotypic antibody or its antigenic determinant that specifically binds to the anti-human TIM-3 antibody according to claim 1, It is characterized in that The amino acid sequence of the heavy chain variable region of the anti-idiotypic antibody or its antigenic determinant that specifically binds to the anti-human TIM-3 antibody is shown in SEQ ID NO.15, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO.

16.

7. The anti-idiotypic antibody or its antigenic determinant that specifically binds to the anti-human TIM-3 antibody according to claim 1, Features The anti-idiotypic antibody that specifically binds to the anti-human TIM-3 antibody is a monoclonal antibody; the antigenic determinant is selected from Fab, F(ab′) 2 or scFv.

8. Use of the anti-idiotypic antibody or its antigenic determinant according to any one of claims 1 to 7 in the preparation of a reagent for detecting anti-TIM-3 antibodies.

9. Use of the anti-idiotypic antibody or its antigenic determinant according to claim 1 in inhibiting the binding of TIM-3 protein to its antibody.

10. The use according to claim 9, Features The antibody against the TIM-3 protein is a monoclonal antibody against the TIM-3 protein.

11. A kit, Features An anti-idiotypic antibody or an antigenic determinant thereof that specifically binds to an anti-human TIM-3 antibody according to any one of claims 1 to 7.

12. The kit according to claim 11, Features The kit contains the anti-idiotypic antibody or its antigenic determinant site that specifically binds to the anti-human TIM-3 antibody according to claims 5 and 6.